DHR vs IDXX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DHR and IDXX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DHR and IDXX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Danaher Corporation is a global science and technology company built around three segments: Biotechnology (bioprocessing tools and consumables used to make biologic drugs, led by Cytiva and Pall), Life Sciences (instruments and reagents for research, including brands like Beckman Coulter Life Sciences, SCIEX, and Leica Microsystems), and Diagnostics (clinical and molecular testing through Beckman Coulter Diagnostics, Radiometer, Leica Biosystems, and Cepheid). A large share of revenue is recurring consumables and service tied to installed instruments and ongoing drug manufacturing, which is the core of the investment appeal. Danaher runs the well-known Danaher Business System, a continuous-improvement operating model it uses to drive margins and integrate acquisitions.

Full DHR guide

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries.

Full IDXX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DHR drivers: Bioprocessing recovery; Recurring consumables and razor-and-blade mix.
• IDXX drivers: The CAG Diagnostics recurring annuity; inVue Dx and the premium installed base.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation is the most cited risk, since DHR often trades at a premium multiple (trailing P/E has ranged roughly from the mid-30s to mid-40s), leaving little room for disappointment. For IDXX, visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~37x forward multiple has a long way to fall.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DHR if you believe its drivers more; IDXX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DHR and IDXX guides.

DHR. Danaher grew 2025 revenue about 2.9% to ~$24.6B with ~2% core growth, while adjusted EPS grew faster on margins and buybacks. The stock has typically carried a premium valuation, with a trailing P/E in the mid-30s to mid-40s and a forward P/E closer to the low 20s as estimates rise. Figures are approximate and as of JULY 2026.

IDXX. At roughly ~$551 a share and a market cap near ~$43B, IDEXX trades at about ~39x trailing earnings and ~37x the midpoint of its own 2026 EPS guidance, and it pays no dividend. That is still a premium to the broader medical device group, though well below the high forties and fifties multiple the stock carried through much of the past five years, and the shares sit close to a 52 week low of ~$519 versus a high of ~$770. Free cash flow of ~$1.25B on ~$4.55B of trailing revenue is a ~28% free cash flow margin, which funded roughly ~$700M of repurchases in the first half of 2026 alone.

Headline figures (approximate, JULY 2026): DHR shows revenue (fy2025) ~$24.6B, adj. diluted eps (fy2025) ~$7.80, free cash flow (fy2025) ~$5.3B, 2026 adj. eps guidance ~$8.35 to $8.55; IDXX shows revenue (ttm) ~$4.55B, up ~13% year over year, cag diagnostics recurring revenue (q2 2026) ~$975M, up ~11%, about ~80% of total revenue, operating margin (q2 2026) ~35.0%, up ~140 basis points year over year, eps (ttm) and valuation ~$14.22 against a ~$551 share price, a ~39x trailing P/E.

DHR and IDXX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DHR and IDXX exposure against your real portfolio. It is not an investment adviser.